Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Shareholder Meeting (May 2006)
16 slides from Neuren Pharmaceuticals's shareholder meeting presentation, May 3, 2006
Slide 1: Cover letter to ASX: Annual General Meeting presentation
Neuren Pharmaceuticals Ltd Level 3, 2-6 Park Avenue, Grafton Auckland, New Zealand office: +64 9 367 7167 fax: +64 9 367 7186 enquiry@neurenpharma.com www.neurenpharma.com 3 May 2006 The Company Announcements Office Australian Stock Exchange Limited BY E-LODGEMENT Dear Sirs NEUREN PHARMACEUTICALS LI
Slide 2: Neuren Pharmaceuticals AGM May 2006
Neuren Pharmaceuticals AGM May 2006
Slide 3: Neuren – Corporate Overview
Neuren – Corporate Overview Neuren is a drug development company Register targeting brain repair & rescue, metabolism and NeuronZ 11.0% cancer NZ Seed Fund Management 10.2% Neuren has an extensive development portfolio Pfizer Inc 7.2% offering several means of delivering value K One W One 5.6% –
Slide 4: Milestones
Milestones NRP collaboration formalised with Metabolic 2005 9 Collaboration with the US Army Walter Reed Army Institute of Research 2005 9 US Army study results show reduced functional deficit from TBI with NNZ-2566 2005 9 Glypromate accelerated into Phase 3 post FDA meeting 2005 9 Glypromate® Phase
Slide 5: Neuren's Two-Pronged Business Strategy
Neuren’s Two-Pronged Business Strategy 1) Focus bulk of resources on drugs in clinical trials 2) Out-license/partner lead molecules in CY2007
Slide 6: Update on Strategy – Part 1
Update on Strategy – Part 1 Two Drug Candidates in Clinical Trials Glypromate® for mild cognitive impairment (MCI) during Coronary Artery Bypass Graft (CABG) surgery is entering Phase 3 Clinical Trials in 2H CY2006 NNZ-2566 (i.v.) for traumatic brain injury (TBI) is currently in Phase 1 Clinical
Slide 7: Phase 3 Glypromate Trial
Phase 3 Glypromate® Trial Excellent Results To Date: Phase 2 trial finishes successfully with no safety issues Final GLP toxicology studies completed—no adverse effects at maximum feasible dose GMP drug manufacturing and quality control program validated Phase 3 Preparation is On Track: Phas
Slide 8: NNZ-2566 in Traumatic Brain Injury
NNZ-2566 in Traumatic Brain Injury Neuren will Now Use Non-Convulsive Seizures as Key Endpoint: US Army and Neuren file joint patent covering effect of NNZ-2566 on non-convulsive seizures and changes in brain wave patterns Changes in brain waves - measured by EEG - seen in stroke and TBI and pre
Slide 9: Update on Strategy – Part 2
Update on Strategy – Part 2 Extensive Pipeline with Attractive Drug Candidates Neuren is not a one product company… – At least 3 other lead candidates : LEAD CANDIDATES NNZ-2566 (ORAL): From 2566 iv Family NNZ-2591 (ORAL): From DKP Family NNZ-4921 (i.v.): From NRP Family – NNZ-2566 (ORAL) and NNZ-
Slide 10: Development Pipeline
Development Pipeline y gy ac n o lo n if c ctio xi c at io f 1 2 3 ad E od u lT o e e se l is Le n al ha s ha s ha ia ry ti o ic Pr ca rc ve ed la lin ia l in i P P P e o at u C er Cl al al al m is c lid rm e- t e- n ic n ic n ic om D Va Fo Pr M a P r C l i C l i C l i C • Glypromate® - MCI CY2006 •
Slide 11: Four Near Term Out-licensing Opportunities
Four Near Term Out-licensing Opportunities NEU does not have the resources to independently develop its entire pipeline NEU has focused on developing four product lines such that they are attractive near-term out-licensing opportunities – Stable compounds – Excellent manufacturing characteristic
Slide 12: Large and Growing Markets
Large and Growing Markets Indication Cases per Year Market Size Effective (USA) US$ Treatment Neuroprotection Bypass Surgery 400,000 $2.0b N Traumatic Brain Injury 1,000,000 $1.0b N Stroke 800,000 $3.5b N Parkinson’s Disease 3,000,000 $2.0b Y/N Alzheimer’s Disease 4,500,000 $2.5b Y/N Multiple Sclero
Slide 13: Conclusion
Conclusion Poised for major milestones
Slide 14: Conclusion
Conclusion Two lead drug candidates are at advanced stage of development and poised for significant clinical milestones – Glypromate® enters Phase 3 in 2H CY2006 – NNZ-2566 Phase 1 underway . TBI collaboration with US Army . Neuren is uniquely positioned to conduct late stage clinical trials for
Slide 15: Key Points of Difference
Key Points of Difference Where else get FDA Phase 3 drug trial for $10M …? – Glypromate ® for MCI • And doesn’t need a partner to move to registration . AND the second drug, again targeting large unmnet need, has arguably the best partner in the world ? – NNZ-2566 in TBI with US Army • And allow
Slide 16: Thank you for your continued support..
Thank you for your continued support..
Neuren Pharmaceuticals — Shareholder Meeting (May 2006) on 6ix